Novo Nordisk reported DKK118.72B in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Bausch Health Companies USD 20.78B 16M Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Merck USD 49.12B 222M Mar/2026
Novartis USD 49.01B 2.02B Jun/2026
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Novo Nordisk DKK 146.38B 27.66B Mar/2026
Pacira USD 363.12M 4.53M Jun/2026
Sanofi EUR 23.58B 3.56B Jun/2026
Supernus Pharmaceuticals USD 40.9M 74K Mar/2026